Molecular structures provide roadmap for targeted Parkinson's disease therapeutics
Researchers at Weill Cornell Medicine have uncovered how a key Parkinson's protein called LRRK2 shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein ...
Aug 10, 2026
0
6









